What’s the Ryplazim deal going to look like?Here’s what I am hoping for:
1. Upfront cash approaching $50M + US for the rights to Ryplazim CD and other IV applications.
2. Royalty payment of 10% on all CD applications and 3-5% on all other acute applications of Ryplazim.
3. R&D program financed by partner with Ryplazim provided by Lmnl, emphasis on acute respiratory disease and other applications.
4. Initial order to support the commercial launch of Ryplazim to be executed by Lmnl on a CMO basis with a guaranteed profit of at least 20% +.
5. Other????
Comments most welcome